Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064756996> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2064756996 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground: Metastatic cancer cells spread through blood vessels where they constantly interact with platelets and leukocytes, forming tumor microemboli and thereby protected from otherwise rapid elimination from host immune defense cells such as NK cells. We previously demonstrated that metastatic cancer cells with aberrant expression or with forced ectopic expression of Natural Killer Immunoglobulin-like Receptors (KIRs) are more resistant to NK killing than those with null or low KIR expression. Here we report that KIR-expressing cancer cells interact more strongly with platelets leading to significantly increase in NK tolerance than those cancer cells with null or low KIR expression. We have demonstrated that certain anti-platelet antagonists are capable of reversing the NK tolerance of these cancer cells in vitro.Methods: Aberrant expressions of KIR genes in metastatic cancers derived from orthotopic rat models were detected by DNA microarray analysis and verified with immunohistochemistry and flow cytometry. Stable transformants with ectopic expression of KIR2DL1 or KIR3DL1 were enriched by cell sorting. Binding of cancer cells with human platelets were analyzed by flow cytometry. NK killing of GFP-tagged cancer cells with differential KIR expressions in the presence and absence of human platelets, with or without pretreatment of anti-platelet antagonists or anti-KIR antibodies, was accessed with a fluorescent plate reader.Results: Using in vitro NK cytotoxic assays, we have found that KIR (aberrant or ectopic) expression or platelet coating on cancers clearly increased their resistance to NK cell killing when compared with parental cells. Interestingly, platelet coating on those metastatic cancer cells with high (aberrant or ectopic) KIR expression increased their IC50 values by 6 to 14 folds respectively when compared with parental cells. We show that NK tolerance correlates positively with platelet coating and the levels of KIR expression on the cancer cells (with correlation coefficient = 0.90 to 0.98), and that the NK resistance is significantly increased when both KIR aberrant expression and platelet coating are present on the cancer cells. However, pretreatment with anti-KIR antibodies and anti-platelet antagonists effectively reverse NK resistance.Conclusion: Aberrant KIR expression on cancer cells enhances their interaction with platelets leading to significant increase in NK tolerance. Anti-platelet antagonists and anti-KIR antibodies alone or in combination may have clinical potential for the treatment or prevention of metastatic and immune resistant cancer cells.Citation Format: Daniel CF Chan, Zhiyong Zhang, Di Zheng, Tiffany Chan, Mary Berg, Kathryn Horwitz, Natalie Ahn, Lewis Lanier, Paul Bunn. Immune-tolerance due to aberrant expression of Natural Killer-Cell Immunoglobulin-like Receptors (KIRs) on cancer cells and enhanced cancer-platelet interactions. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4836. doi:10.1158/1538-7445.AM2014-4836" @default.
- W2064756996 created "2016-06-24" @default.
- W2064756996 creator A5000763253 @default.
- W2064756996 creator A5005594330 @default.
- W2064756996 creator A5012170857 @default.
- W2064756996 creator A5021905687 @default.
- W2064756996 creator A5026049918 @default.
- W2064756996 creator A5032159655 @default.
- W2064756996 creator A5036834791 @default.
- W2064756996 creator A5066949514 @default.
- W2064756996 creator A5071670695 @default.
- W2064756996 date "2014-09-30" @default.
- W2064756996 modified "2023-09-22" @default.
- W2064756996 title "Abstract 4836: Immune-tolerance due to aberrant expression of Natural Killer-Cell Immunoglobulin-like Receptors (KIRs) on cancer cells and enhanced cancer-platelet interactions" @default.
- W2064756996 doi "https://doi.org/10.1158/1538-7445.am2014-4836" @default.
- W2064756996 hasPublicationYear "2014" @default.
- W2064756996 type Work @default.
- W2064756996 sameAs 2064756996 @default.
- W2064756996 citedByCount "0" @default.
- W2064756996 crossrefType "proceedings-article" @default.
- W2064756996 hasAuthorship W2064756996A5000763253 @default.
- W2064756996 hasAuthorship W2064756996A5005594330 @default.
- W2064756996 hasAuthorship W2064756996A5012170857 @default.
- W2064756996 hasAuthorship W2064756996A5021905687 @default.
- W2064756996 hasAuthorship W2064756996A5026049918 @default.
- W2064756996 hasAuthorship W2064756996A5032159655 @default.
- W2064756996 hasAuthorship W2064756996A5036834791 @default.
- W2064756996 hasAuthorship W2064756996A5066949514 @default.
- W2064756996 hasAuthorship W2064756996A5071670695 @default.
- W2064756996 hasConcept C121608353 @default.
- W2064756996 hasConcept C154317977 @default.
- W2064756996 hasConcept C159654299 @default.
- W2064756996 hasConcept C202751555 @default.
- W2064756996 hasConcept C203014093 @default.
- W2064756996 hasConcept C502942594 @default.
- W2064756996 hasConcept C54355233 @default.
- W2064756996 hasConcept C553184892 @default.
- W2064756996 hasConcept C55493867 @default.
- W2064756996 hasConcept C81885089 @default.
- W2064756996 hasConcept C86803240 @default.
- W2064756996 hasConcept C8891405 @default.
- W2064756996 hasConcept C96232424 @default.
- W2064756996 hasConcept C97037327 @default.
- W2064756996 hasConceptScore W2064756996C121608353 @default.
- W2064756996 hasConceptScore W2064756996C154317977 @default.
- W2064756996 hasConceptScore W2064756996C159654299 @default.
- W2064756996 hasConceptScore W2064756996C202751555 @default.
- W2064756996 hasConceptScore W2064756996C203014093 @default.
- W2064756996 hasConceptScore W2064756996C502942594 @default.
- W2064756996 hasConceptScore W2064756996C54355233 @default.
- W2064756996 hasConceptScore W2064756996C553184892 @default.
- W2064756996 hasConceptScore W2064756996C55493867 @default.
- W2064756996 hasConceptScore W2064756996C81885089 @default.
- W2064756996 hasConceptScore W2064756996C86803240 @default.
- W2064756996 hasConceptScore W2064756996C8891405 @default.
- W2064756996 hasConceptScore W2064756996C96232424 @default.
- W2064756996 hasConceptScore W2064756996C97037327 @default.
- W2064756996 hasLocation W20647569961 @default.
- W2064756996 hasOpenAccess W2064756996 @default.
- W2064756996 hasPrimaryLocation W20647569961 @default.
- W2064756996 hasRelatedWork W1953507628 @default.
- W2064756996 hasRelatedWork W1996167174 @default.
- W2064756996 hasRelatedWork W2023082289 @default.
- W2064756996 hasRelatedWork W2046250975 @default.
- W2064756996 hasRelatedWork W2059063810 @default.
- W2064756996 hasRelatedWork W2127338928 @default.
- W2064756996 hasRelatedWork W2172155243 @default.
- W2064756996 hasRelatedWork W2179970566 @default.
- W2064756996 hasRelatedWork W2317084993 @default.
- W2064756996 hasRelatedWork W2469623424 @default.
- W2064756996 hasRelatedWork W2535026985 @default.
- W2064756996 hasRelatedWork W2554663616 @default.
- W2064756996 hasRelatedWork W2576916496 @default.
- W2064756996 hasRelatedWork W2585500343 @default.
- W2064756996 hasRelatedWork W2589652186 @default.
- W2064756996 hasRelatedWork W2593359380 @default.
- W2064756996 hasRelatedWork W2767246402 @default.
- W2064756996 hasRelatedWork W2806906871 @default.
- W2064756996 hasRelatedWork W2811504077 @default.
- W2064756996 hasRelatedWork W2991964613 @default.
- W2064756996 isParatext "false" @default.
- W2064756996 isRetracted "false" @default.
- W2064756996 magId "2064756996" @default.
- W2064756996 workType "article" @default.